BD Life Sciences completes acquisition of Cellular Research

BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today announced it has completed the acquisition of Cellular Research, Inc.

BD is a global leader in characterizing and isolating single cells for analysis, with more than 30 years of experience in developing cell sorting technologies, known collectively as flow cytometry. This acquisition sets the stage for the next generation of commercial tools in the field of single cell genomic analysis, widely acknowledged by leading academic and industry researchers as the next frontier of biological discovery and clinical advancement. Cellular Research has developed advanced tools for massively parallel single cell genetic analysis based on their proprietary Molecular Indexing technology to enable gene expression profiles from single cells.

Combined, the BD and Cellular Research technologies provide researchers an integrated sample prep workflow to quantify and study gene expression in large numbers of individual cells, enabling higher resolution biology. The comprehensive workflow is intended to enable researchers to make new discoveries in single cell analysis, promoting the understanding of the genomic diversity of single cells and helping to identify new approaches for targeted clinical diagnostics and therapies in important fields such as immunology, immune-oncology and personalized medicine.

"The acquisition of Cellular Research, combined with our existing cell sorting technology, will provide our customers with a more complete and simplified workflow solution for single cell analysis," said Linda Tharby, executive vice president and president of BD Life Sciences. "The addition of Cellular Research builds on our GenCell acquisition and underscores BD's commitment to a genomics strategy focused on next generation sequencing (NGS) sample preparation."

Since September 2014, BD and Cellular Research have had a collaboration to develop single cell analysis workflows for Cellular Research's Precise product line and BD's FACS instruments and software. The collaboration resulted in a study presented at Advances in Genome Biology and Technology (AGBT) Meeting that demonstrated the combined workflow enhances the detection and quantification of gene expression in single and/or multiple cell samples.

"Integrating BD's single cell sorting capabilities and world-leading expertise with our next generation single cell genomic technologies will provide researchers with a scalable, cost-effective approach to high resolution gene expression studies," said Stephen Fodor, Ph.D., chief executive officer and co-founder of Cellular Research. "We are excited about the possibilities we can offer researchers by combining our expertise, and believe it has the potential to meet several unmet needs in single cell genomics research."

Additional terms of the agreement were not disclosed.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BD (Becton, Dickinson and Company). (2019, June 19). BD Life Sciences completes acquisition of Cellular Research. News-Medical. Retrieved on June 16, 2024 from

  • MLA

    BD (Becton, Dickinson and Company). "BD Life Sciences completes acquisition of Cellular Research". News-Medical. 16 June 2024. <>.

  • Chicago

    BD (Becton, Dickinson and Company). "BD Life Sciences completes acquisition of Cellular Research". News-Medical. (accessed June 16, 2024).

  • Harvard

    BD (Becton, Dickinson and Company). 2019. BD Life Sciences completes acquisition of Cellular Research. News-Medical, viewed 16 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Thun Hospital use BD's Pyxis MedStation™ system to automate medication management